Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: Correlation with JAK2V617F mutational status and cytoreductive therapy

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2388-2395

  Treliński, Jacek ^a   Chojnowski, Krzysztof ^a   Cebula Obrzut, Barbara ^a   Smolewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anagrelide; Apoptosis; Essential thrombocythemia; Hydroxyurea; JAK2V617F mutation

Indexed keywords

ANAGRELIDE; CASPASE 3; HYDROXYUREA; JANUS KINASE 2; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOWN REGULATION; FEMALE; HUMAN; MALE; MEGAKARYOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BONE MARROW CELLS; FEMALE; HUMANS; HYDROXYUREA; JANUS KINASE 2; MALE; MEGAKARYOCYTES; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84868004305     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0202-3     Document Type: Article

References (37)

1. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002;26:551-9.
2. Schattner EJ. Apoptosis in lymphocytic leukemias and lymphomas. Cancer Invest. 2002;20:737-48.
3. Castro FA, Jacysyn JF, Ulbrich AG, et al. Overexpression of the anti-apoptotic genes mcl-1, bcl-w, bcl-xL and a1 is corellated with Chronic Myelogenous Leukemia progression and resistance to Gleevec. ASH Annual Meeting Abstract. Blood. 2005;106:P2880.
4. Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110:986-93.
5. Tognon R, Gasparotto EP, Leroy JM, Oliveira GL, Neves RP, Carrara Rde C, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Velano CE, Simões BP, Alberto FL, Miyashiro K, de Souza AM, Amarante-Mendes GP, de Castro FA. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. J Clin Pathol. 2011;64:75-82.
6. Tefferi ANA, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61.
8. Florena AM, Tripodo C, Di Bernardo ANA, Iannitto E, Guarnotta C, Porcasi R, Ingrao S, Abbadessa V, Franco VS. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis. J Clin Pathol. 2009;62:331-8.
9. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian cass: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424.
10. Ekert PG, Silke J, Vaux DL. Cas inhibitors. Cell Death Differ. 1999;6:1081-6.
11. Nicholson DW. Cas structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999;6:1028-42.
12. Silva M, Richard C, Benito ANA, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564-71.
13. Zhang L, Zhao H, Sun A, Lu S, Liu B, Tang F, Feng Y, Zhao L, Yang R, Han ZC. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia. Haematologica. 2004;89:1199-206.
14. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112:2190-8.
15. Vizmanos JL, Ormazábal C, Larráyoz MJ, Cross NC, Calasanz MJ. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia. 2006;20:534-5.
16. Zeuner ANA, Pedini F, Signore M, Ruscio G, Messina C, Tafuri ANA, Girelli G, Peschle C, De Maria R. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood. 2006;107:3495-502.
17. Wang W, Prince CZ, Mou Y, Pollman MJ. Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J Biol Chem. 2002;14(277):21723-9.
18. Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC, Walsh K. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the Cas-8 inhibitor FLIP. J Biol Chem. 2004;279:1513-25.
19. Stärck L, Scholz C, Dörken B, Daniel PT. Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol. 2005;35:1257-66.
20. Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M, Martinelli G, Baccarani M, Vianelli N. JAK2 V617F mutation in Essentials thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma. 2009;50:247-53.
21. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi ANA. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159-66.
22. Carobbio ANA, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi ANA, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;15(109):2310-3.
23. Finazzi G, Rambaldi ANA, Guerini V, Carobbo ANA, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2V617F mutation status. Haematologica. 2007;92:135-6.
24. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132-6.
25. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
26. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol. 1992;19:1-10.
27. Falanga ANA, Marchetti M, Vignoli ANA, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523-30.
28. Maugeri N, Giordano G, Petrilli MP, Fraticelli V, de Gaetano G, Cerletti C, Storti S, Donati MB. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost. 2006;4:2593-8.
29. Treliński J, Tybura M, Smolewski P, Robak T, Chojnowski K. The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. Blood Coagul vs Fibrinolysis. 2009;20:646-51.
30. Zeng Y, Liu XH, Shen Y, Lai Y, Liu XJ. Laminar shear stress promotes endothelial cell migration and inhibits cell apoptosis in the presence of hydroxyurea. Cell Mol Biol (Noisy-le-grand). 2011; 57 Suppl:OL1550-1557.
31. Cui P, Lin Q, Xin C, Han L, An L, Wang Y, Hu Z, Ding F, Zhang L, Hu S, Hang H, Yu J. Hydroxyurea-induced global transcriptional suppression in mouse ES cells. Carcinogenesis. 2010;31(9):1661-8.
32. Huyghe P, Dassonneville L, Fenaux P, Bailly C. Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line. Oncol Res. 2004;14:235-45.
33. Woo GH, Bak EJ, Nakayama H, Doi K. Molecular mechanisms of hydroxyurea (HU)-induced apoptosis in the mouse fetal brain. Neurotoxicol Teratol. 2006;28:125-134.
34. Emadi ANA, Spivak JL. Anagrelide: 20 years later. Expert Rev Anticancer Ther. 2009;9:37-50.
35. Thiele J, Kvasnicka HM, Schmitt-Graeff ANA. Effects of anagrelide on megakaryopoiesis and platelet production. Semin Thromb Hemost. 2006;32:352-61.
36. Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia. 2006;20:1117-22.
37. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829-33.